Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patientswith relapsed multiple myeloma

1. Stewart, A.K.
2. Dimopoulos, M.A.
3. Masszi, T.
4. Špička, I.
5. Oriol, A.
6. Hájek, R.
7. Rosiñol, L.
8. Siegel, D.S.
9. Niesvizky, R.
10. Jakubowiak, A.J.
11. San-Miguel, J.F.
12. Ludwig, H.
13. Buchanan, J.
14. Cocks, K.
15. Yang, X.
16. Xing, B.
17. Zojwalla, N.
18. Tonda, M.
19. Moreau, P.
20. Palumbo, A.